We believe ChemoCentryx has established the broadest pipeline of novel drugs targeting chemokine receptors in the pharmaceutical industry. We are internally discovering and developing several clinical- or preclinical-stage small molecule compounds, each targeting a distinct chemokine or chemoattractant receptor. Our compounds are designed to be highly potent, selective to minimize the risk of off-target effects and orally-available for improved patient compliance. As small molecules, they are also easier and less costly to manufacture than protein therapeutics, or biologics.
Vercirnon (also known as Traficet-EN or CCX282) targets the chemokine receptor known as CCR9. Vercirnon is our Phase III-ready drug candidate for the treatment of patients with moderate-to-severe Crohn's disease. CCX140, our lead independent drug candidate, which targets the CCR2 chemokine receptor, successfully completed a trial for Type 2 diabetes and is currently in two Phase II clinical trials in patients with diabetic nephropathy, a form of kidney disease. CCX354, a CCR1 inhibitor, successfully completed a Phase II proof-of-concept clinical trial for the treatment of rheumatoid arthritis, or RA. CCX168, a C5aR inhibitor, completed Phase I clinical evaluation and is currently in a Phase II trial for the treatment of anti-neutrophil cytoplasmic antibody, or ANCA-associated vasculitis, or AAV. CCX872, our independent next generation CCR2 drug candidate for the treatment of expanded indications of renal disease, is in a Phase I clinical trial. CCX507, our independent drug candidate for the treatment of inflammatory bowel disease, or IBD resulted from our de novo CCR9 program and is also in a Phase I clinical trial.
In addition, we have several programs currently in development candidate selection which target one of several novel chemokine or chemoattractant receptors.
^ Return to Top